首页> 美国卫生研究院文献>Thorax >Comparative dose-response study of three anticholinergic agents and fenoterol using a metered dose inhaler in patients with chronic obstructive pulmonary disease.
【2h】

Comparative dose-response study of three anticholinergic agents and fenoterol using a metered dose inhaler in patients with chronic obstructive pulmonary disease.

机译:慢性阻塞性肺疾病患者使用计量吸入器对三种抗胆碱药和非诺特罗的剂量反应比较研究。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BACKGROUND--Inhaled anticholinergics and beta agonists are widely used in the treatment of patients with chronic obstructive pulmonary disease (COPD). However, dosage requirements have not been thoroughly evaluated and comparative dose-response data for these agents are limited. METHODS--Twenty men with stable COPD of mean (SD) age 69.4 (5.8) years and FEV1 0.93 (0.38) litres were studied in randomised, double blind, crossover, placebo controlled experiments. All of the patients received two, four, eight, and 16 puffs of ipratropium bromide (20 micrograms/puff), flutropium bromide (30 micrograms/puff), oxitropium bromide (100 micrograms/puff), fenoterol (200 micrograms/puff), or placebo in random order on five separate days. Doses were administered by a metered dose inhaler at intervals of 60 minutes to give cumulative doses of two, six, 14, and 30 puffs. Five mg of nebulised salbutamol was administered 60 minutes after the patient had received the final 16 puffs of each regimen. Forced expiratory volume in one second (FEV1), forced vital capacity (FVC), heart rate, and blood pressure were measured five minutes before each treatment and 30 minutes after treatment with nebulised salbutamol. RESULTS--FEV1 and FVC reached a plateau after administration of a cumulative dose of 14 puffs of ipratropium bromide (280 micrograms) or flutropium bromide (420 micrograms), and after six puffs of oxitropium bromide (600 micrograms). There were no differences with respect to maximum increases in FEV1 and FVC amongst the three anticholinergic agents. However, after six puffs oxitropium bromide produced a greater increase in FEV1 than either ipratropium bromide or flutropium bromide. Fenoterol caused a greater increase in both FEV1 and FVC than the three anticholinergic agents after six puffs, as well as a greater increase in pulse rate. Oxitropium bromide produced a greater increase in pulse rate than the other anticholinergics after 14 puffs. The incidence of side effects was dose-related and notable adverse effects were reported after 30 puffs of ipratropium bromide, 14 puffs of oxitropium bromide, and two puffs of fenoterol. CONCLUSIONS--Oxitropium bromide produced a greater bronchodilator effect than either ipratropium bromide or flutropium bromide when used at doses of less than six puffs, without apparent side effects. There were, however, no differences in maximal response between these drugs. Fenoterol may have a greater peak bronchodilator effect than the anticholinergic agents but it causes more adverse effects, even at lower doses. Depending upon the balance between efficacy and side effects, oxitropium bromide may be preferred in the treatment of patients with COPD.
机译:背景技术-吸入性抗胆碱药和β受体激动剂被广泛用于治疗慢性阻塞性肺疾病(COPD)的患者。但是,剂量要求尚未得到彻底评估,这些药物的比较剂量反应数据有限。方法-在随机,双盲,交叉,安慰剂对照实验中研究了20名平均COPD稳定(SD)平均年龄(SD)69.4(5.8)岁,FEV1 0.93(0.38)升的男性。所有患者均接受了2,4,8和16抽吸的异丙托溴铵(20微克/粉扑),氟托溴铵(30微克/粉扑),溴化氧(100微克/粉扑),非诺特罗(200微克/粉扑),或安慰剂按随机顺序在五天之内服用。通过计量吸入器以60分钟的间隔给药,以产生2,6,14和30抽吸的累积剂量。在患者接受每种方案的最后16次抽吸后60分钟,给予5 mg雾化的沙丁胺醇。在每次治疗前5分钟和雾化沙丁胺醇治疗30分钟后,测量一秒钟的强制呼气量(FEV1),强制肺活量(FVC),心率和血压。结果-在累计剂量14喷异丙托溴铵(280微克)或氟托溴铵(420微克)给药后,以及六剂吸氧溴化氧(600微克)后,FEV1和FVC达到稳定期。在三种抗胆碱能药物之间,FEV1和FVC的最大增加没有差异。但是,经过六次抽吸后,与异丙托溴铵或氟托溴铵相比,溴索托溴铵在FEV1方面的增加更大。六次吞吐后,非诺特罗引起的FEV1和FVC的增加均大于三种抗胆碱药,并且脉搏率的增加也更大。 14次抽吸后,溴氧噻托铵比其他抗胆碱药产生更大的脉搏增加率。副反应的发生与剂量有关,据报道,在服用30克异丙托溴铵,14克溴托昔铵和2克非诺特罗之后,出现了明显的不良反应。结论-当剂量少于6抽吸时,溴索托溴铵比异丙托溴铵或氟托溴铵产生更大的支气管扩张作用,而没有明显的副作用。但是,这些药物之间的最大反应没有差异。非诺特罗的支气管扩张剂峰值作用可能比抗胆碱能药更大,但即使在较低剂量下,它也会引起更多的不良反应。根据疗效和副作用之间的平衡,在治疗COPD患者中,溴化氧托溴铵可能更可取。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号